Eli Lilly (LLY) and Verve Therapeutics (VERV) said Thursday that the former's tender offer to acquire Verve expired on Wednesday with about 55.7% of Verve outstanding shares validly tendered, allowing Eli Lilly to move ahead with completing the acquisition.
Eli Lilly and Verve said shareholders who tendered their shares will receive $10.50 per share in cash along with a non-tradable contingent value right worth up to $3 based on achieving a specific milestone.
The acquisition is expected to be finalized Friday, the companies said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.